| 纯度 | >90%SDS-PAGE. |
| 种属 | mouse |
| 靶点 | Lgals6 |
| Uniprot No | O54891 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-301aa |
| 氨基酸序列 | MAYVPAPGYQPTYNPTLPYKRPIPGGLSVGMSFYIQGTAKENMRRFHVNFAVGQDDGADVAFHFNPRFDGWDKVVFNTKQSGRWGKEEEKSMPFQKGKHFELVFMVMPEHYKVVVNGSPFYEYGHRLPVQMVTHLQVDGDLELQSINFFGVQPAETKYPAMTGPPVFNPCLPYVGALQGGFTVRRTIIIKGYVLPTAKTFAINFRVGSSEDIALHINPRIGDCLVRNSYMNGSWGTEERMVAYNPFGPGQFFDLSIRCGMDRFKVFANGIHLFNFSHRFQALRKINTLEINGDLTLSYVHI |
| 预测分子量 | 61.1 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于Lgals6(半乳糖凝集素-6)重组蛋白的**示例参考文献**(内容为模拟，建议通过学术数据库验证)：
---
1. **文献名称**: *"Recombinant Human Galectin-6 Expression and Its Role in Intestinal Immunity"*
**作者**: Zhang Y, et al.
**摘要**: 研究报道了在昆虫细胞系统中重组表达人源Lgals6蛋白，并发现其通过结合肠道上皮细胞表面糖基化修饰，调节肠道免疫稳态，抑制过度炎症反应。
2. **文献名称**: *"Structural and Functional Analysis of Mouse Galectin-6 in Bacterial Infection Models"*
**作者**: Tanaka K, et al.
**摘要**: 通过大肠杆菌表达重组小鼠Lgals6.解析其晶体结构，并证明其通过结合病原体表面多糖增强巨噬细胞的吞噬功能，提示其在抗感染中的作用。
3. **文献名称**: *"Galectin-6 Recombinant Protein Attenuates Liver Fibrosis via Modulating Hepatic Stellate Cell Activation"*
**作者**: Wang L, et al.
**摘要**: 利用哺乳动物细胞表达的重组Lgals6蛋白，在小鼠模型中验证其通过抑制TGF-β信号通路减轻肝纤维化，为潜在治疗策略提供依据。
4. **文献名称**: *"High-Yield Production of Recombinant Galectin-6 in Pichia pastoris and Its Glycan-Binding Specificity"*
**作者**: Müller S, et al.
**摘要**: 描述在毕赤酵母系统中高效表达重组Lgals6.并通过糖结合实验揭示其对特定N-连接聚糖的高亲和力，拓展了其在糖生物学研究中的应用。
---
**建议**：可通过PubMed、Google Scholar等平台以关键词 **"Lgals6 recombinant"** 或 **"Galectin-6 expression"** 检索最新文献，重点关注功能研究、结构分析或疾病模型应用方向。
Lgals6. also known as galectin-6. is a member of the galectin family of β-galactoside-binding proteins characterized by a conserved carbohydrate recognition domain (CRD). This protein is primarily expressed in the gastrointestinal tract, particularly in the small intestine, and plays roles in cell adhesion, immune regulation, and tissue homeostasis. Galectins are implicated in modulating inflammation, apoptosis, and cell signaling, with Lgals6 showing species-specific expression patterns; for instance, it is well-studied in mice but lacks a direct functional ortholog in humans.
Recombinant Lgals6 protein is engineered using expression systems like Escherichia coli or mammalian cells to produce purified, bioactive forms for research. Its production enables detailed study of molecular interactions, particularly its binding affinity for glycoconjugates on cell surfaces or extracellular matrices. Researchers utilize recombinant Lgals6 to explore its involvement in intestinal immunity, microbial interactions, and potential contributions to diseases such as colitis or cancer. Studies suggest it may regulate T-cell responses or influence gut microbiota composition, though its precise mechanisms remain under investigation.
The development of recombinant Lgals6 has facilitated structural analyses, antibody generation, and in vitro/in vivo functional assays, advancing understanding of galectin-mediated pathways. Its applications extend to drug discovery, aiming to target galectin-related pathologies. However, challenges persist in reconciling murine models with human biology due to evolutionary divergence. Ongoing research focuses on elucidating Lgals6's role in mucosal immunity and its therapeutic potential, highlighting its relevance in both basic science and translational medicine.
×
